Lucitanib

Overview

Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR , potently and selectively inhibits VEGFR1 , VEGFR2 , VEGFR3 , FGFR1 and FGFR2 with IC 50 s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-15391
• CAS No.: 1058137-23-7
• Molecular Formula: C26H25N3O4
• Molecular Weight: 443.49
• Purity: 98.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution
• Availability: In-stock

Source

Original product source